publication date: Feb. 2, 2018
Issue 5 - Feb. 2, 2018
To access this members-only content, please log in.
If you're not a subscriber why not join today?
If you believe you should be able to view this area but cannot log in, then please contact us and we will try to rectify this issue as soon as possible.
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.
  • Like it or not, CMS policy aims to change everything in Next generation sequencing

    A policy now in the works at the Centers for Medicare and Medicaid Services will define settings where Medicare will pay for next generation sequencing.

    The health care funding agency will use FDA approval of NGS tests to determine whether these tests are covered outright, receive “coverage with evidence development,” or are denied coverage altogether.

  • Dear CMS, Here’s what I think about your NGS policy… Agency draft memo garners 315 comments

    The range of opinions reflected in the 315 comments CMS received on its proposal for Medicare payment for Next Generation Sequencing reflects the extent of controversy over the test.

  • Conversation with the Cancer Letter

    Miller: “Doctors and patients have confidence in knowing that a test has gone through FDA”

    Concurrent FDA approval and the establishment of Medicare coverage will propel Next generation sequencing squarely into the mainstream of oncology practice, said Vincent Miller, chief medical officer of Foundation Medicine Inc.

  • In Brief

    • Mays Family Foundation makes legacy gift of $30 million to UT Health San Antonio Cancer Center
    • Sylvester Comprehensive Cancer Center to build proton therapy program
    • Syapse partners with Seoul National University Hospital and Megazone
    • Buchholz named medical director at Scripps MD Anderson Cancer Center
    • Kati Stoermer named executive director NRG Oncology
    • James Wade joins Vibrent Health as chief medical informatics officer
    • SU2C announces $11 million multi-disciplinary research program
    • Chen, Bild, Kahn, Heisterkamp join City of Hope
    • New building expands inpatient care at Siteman Cancer Center
    • CancerCare raises nearly $665,000 to support patients affected by hurricanes
    • Cancer Support Community adds Digital Nonprofit MyLifeLine to its network
  • Funding Opportunities

    AACR announces AACR-J&J lung cancer innovation science grants

    The American Association for Cancer Research has launched the AACR-Johnson & Johnson Lung Cancer Innovation Science Grants.

    A total of $4.5 million will be made available in research funding. Three multi-institutional research teams that seek novel approaches to the prevention, interception, and cure of lung cancer will each be awarded up to $1.5 million over three years.

  • TCCL Logo

  • Trials and Tribulations

    Re: Drug Pricing My unsolicited advice to HHS Secretary Alex Azar

    Dear Mr. Azar:

    I am the leader of CancerCare, a national organization that provides free, professional support services to anyone affected by cancer. I’m writing this letter to offer some perspective regarding the plight of nearly 16 million U.S. cancer survivors, the many more who are family and care providers, and all of those who will be diagnosed in the coming years.

  • Clinical Roundup

    Trial shows durable remissions with Kymriah in children, young adults with r/r ALL

    Novartis has announced updated results from the pivotal ELIANA clinical trial of Kymriah (tisagenlecleucel), formerly CTL019, in relapsed or refractory (pediatric and young adult patients with B-cell acute lymphoblastic leukemia have been published in The New England Journal of Medicine. New data include longer-term follow-up and efficacy in 75 infused patients, analysis of expansion and persistence of Kymriah, and longer-term safety.

  • Drugs and Targets

    • FDA approves lutetium Lu 177 dotatate for treatment of GEP-NETS
    • Amgen receives CHMP positive opinion to add updated survival data to Kyprolis label
    • Syndax announces immuno-oncology collaboration with AstraZeneca

Copyright (c) 2018 The Cancer Letter Inc.